Secondary Prevention After Coronary Artery Bypass Graft Surgery

Kulik, Alexander; Ruel, Marc; Jneid, Hani; Ferguson, T. Bruce; Hiratzka, Loren F.; Ikonomidis, John S.; López-Jiménez, Francisco; McNallan, Sheila M; Patel, Mahesh J.; Roger, Véronique L.; Sellke, Frank W.; Sica, Domenic A.; Zimmerman, Lani

doi:10.1161/cir.0000000000000182

Cited by 346 publications

(216 citation statements)

References 478 publications

(508 reference statements)

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…29 The 2015 American Heart Association Scientific Statement lists preoperative and postoperative aspirin as a Class I recommendation after surgical coronary revascularization. 30 Lipid management is also important for preventing progression of native coronary disease and venous graft disease. 30 Statin therapy begun at the time of hospital discharge has been associated with improved survival in Japanese patients undergoing their first coronary revascularization by percutaneous coronary intervention or CABG.…”

Section: Discussionmentioning

confidence: 99%

“…30 Lipid management is also important for preventing progression of native coronary disease and venous graft disease. 30 Statin therapy begun at the time of hospital discharge has been associated with improved survival in Japanese patients undergoing their first coronary revascularization by percutaneous coronary intervention or CABG. 31 Consistent with this finding, the 2015 American Heart Association Scientific Statement recommended that, unless contraindicated, all CABG patients should receive statin therapy, starting in the preoperative period and restarting soon after surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is Bilateral Internal Mammary Arterial Grafting Beneficial for Patients Aged 75 Years or Older?

Itoh

Kimura

Adachi

et al. 2016

Circ J

View full text Add to dashboard Cite

Background: Although bilateral internal mammary artery (BIMA) grafting is performed with increasing regularity in elderly patients, whether it is truly beneficial, and therefore indicated, in these patients remains uncertain. We retrospectively investigated early and late outcomes of BIMA grafting in patients aged ≥75 years. Methods and Results:We identified 460 patients aged ≥75 years from among 2,618 patients who underwent either single internal mammary artery (SIMA) grafting (n=293) or BIMA grafting (n=107). Early outcomes did not differ between the SIMA and BIMA patients (30-day mortality: 1.7% vs. 0%, P=0.39; sternal wound infection: 1.0% vs. 4.7%; P=0.057). Late outcomes, 10-year survival in particular, were improved in the BIMA group (36.6% vs. 48.1%, P=0.033). In the analysis of the results in propensity score-matched groups (196 patients in the SIMA group, 98 patients in the BIMA group), improved 10-year survival was documented in the BIMA group (34.8% vs. 47.6%, P=0.030). Cox proportional regression analysis showed SIMA usage (non-use of BIMA) to be a predictor for late mortality (hazard ratio: 0.65, 95% confidence interval: 0.43-0.98, P=0.042). We further compared outcomes between the total non-elderly patients (n=2,158) and total elderly patients (n=460). BIMA usage was similar, as was 30-day mortality (1.0% vs. 1.3%, respectively). Conclusions:A survival advantage, with no increase in early mortality, can be expected from BIMA grafting in patients aged ≥75 years. (Circ J 2016; 80: 1756 -1763

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Is Bilateral Internal Mammary Arterial Grafting Beneficial for Patients Aged 75 Years or Older?

Itoh

Kimura

Adachi

et al. 2016

Circ J

View full text Add to dashboard Cite

show abstract

“…One clinical trial, which was conducted in Japan and focused on diabetes, failed to find significant differences, although the study was underpowered 31. The American Heart Association, in recent scientific statements, emphasized stricter criteria for aspirin use in high‐risk individuals balancing benefits and harm 8, 9, 10, 11. These reports could have changed aspirin use patterns since 2009.…”

Section: Discussionmentioning

confidence: 99%

“…After review of data from multiple prospective randomized clinical trials,4, 5, 6 the United States Preventive Services Task Force (USPSTF) in 2009 published a strong 1A recommendation in favor of use of low‐dose aspirin for primary prevention in men aged 45 to 79 years and women aged 55 to 79 years in whom benefit would be anticipated to exceed risk 7. The recommendation in favor of aspirin use was also included in an American Heart Association prevention guidelines,8, 9, 10, 11 the recent Healthy People 2020 plan,12 and the “Million Hearts Initiative” of the Centers for Medicare and Medicaid Services and Centers for Disease Control and Prevention 13…”

Section: Introductionmentioning

confidence: 99%

Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980–2009: The Minnesota Heart Survey

Luepker

Steffen

Duval

et al. 2015

JAHA

View full text Add to dashboard Cite

BackgroundDaily low‐dose aspirin is recommended for primary prevention of myocardial infarction and stroke in higher‐risk patients. Population trends in aspirin use for cardiovascular disease (CVD) prevention in an urban population (Minneapolis/St. Paul, 2010 population 2.85 million) from 1980 to 2009 were evaluated.Methods and ResultsSurveys of randomly selected adults aged 25 to 74 years were collected at 5‐year intervals. Self‐reports of regular aspirin use for CVD prevention and history of CVD were obtained. Six cross‐sectional surveys included 12 281 men and 14 258 women. Age‐adjusted aspirin use for primary prevention increased during this period from 1% to 21% among men and 1% to 12% among women. Aspirin use was highest in those aged 65 to 74 years. For secondary prevention, age‐adjusted aspirin use increased from 19% to 74% among men and 11% to 64% among women. While data are based on self‐report, a substudy using a biochemical indicator of aspirin use (serum thromboxane B2) supports the validity of self‐report.ConclusionsAspirin for CVD prevention is commonly used by a large and growing portion of the general population. It is not known if this is based on professional advice or self‐prescribed use. It is also likely that many who would benefit do not use aspirin and others use aspirin inappropriately.

show abstract

“…The most specific guideline from Europe [4] dates from 2008, and the American one is from 2014 [10]. The 2014 guideline issued by the European Association for Cardio-Thoracic Surgery [11] is not clear on this issue and focusses more on percutaneous revascularisation than CABG.…”

mentioning

confidence: 99%

Antiplatelet therapy with CABG: chaos in the Netherlands

Verheugt

2017

Neth Heart J

View full text Add to dashboard Cite

Secondary Prevention After Coronary Artery Bypass Graft Surgery

Cited by 346 publications

References 478 publications

Is Bilateral Internal Mammary Arterial Grafting Beneficial for Patients Aged 75 Years or Older?

Is Bilateral Internal Mammary Arterial Grafting Beneficial for Patients Aged 75 Years or Older?

Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980–2009: The Minnesota Heart Survey

Antiplatelet therapy with CABG: chaos in the Netherlands

Contact Info

Product

Resources

About